Skip to main content
AIDS Research and Therapy logoLink to AIDS Research and Therapy
. 2024 Dec 20;21:95. doi: 10.1186/s12981-024-00686-5

Brief Communication: Factors associated with willingness to use long-acting injectable Cabotegravir for HIV pre-exposure prophylaxis (PrEP) among female undergraduate students at a Ugandan university

Bridget Atuhaire 1, Laban Muteebwa 2, Racheal Nabunya 3, Richard Muhindo 1, Tom Denis Ngabirano 1, Charles Peter Osingada 4, Patience A Muwanguzi 1,
PMCID: PMC11662602  PMID: 39707475

Abstract

Background

We assessed the willingness of female students at a Ugandan public university to use long-acting Cabotegravir (CAB-LA) for HIV prevention, given their high prevalence of HIV risk behaviours.

Methods

Using an online questionnaire, this cross-sectional study surveyed 346 female undergraduate students aged 18–25. Factors influencing their willingness were analysed with modified Poisson regression and robust standard errors.

Results

More than half, 56.7% (95% CI: 51.4 to 61.8), were willing to use CAB-LA. Willingness was significantly associated with being sexually active in the past 3 months, using alcohol in the past 6 months, or being in the 4th year of study compared to the 1st year.

Conclusion

Educational initiatives on innovative HIV prevention strategies, such as CAB-LA, should be introduced early in university students’ studies to increase awareness and acceptance.

Keywords: Long-acting cabotegravir, Pre-exposure prophylaxis, Students, Willingness

Background

Pre-exposure prophylaxis (PrEP) involves HIV-negative individuals using antiretroviral (ARV) drugs to prevent HIV infection before exposure. Despite its effectiveness, issues like adherence hinder its uptake [1]. In Uganda, oral PrEP is available at over 260 facilities, but its use is suboptimal among some priority groups [2]. Long-acting injectable Cabotegravir (CAB-LA) could address limitations of daily pills and has shown greater efficacy in preventing HIV compared to oral PrEP [3]. CAB-LA, administered every eight weeks, has demonstrated significant reductions in HIV infection rates in various studies [4]. However, challenges such as awareness, access, injection pain, and potential side effects persist [5]. Although CAB-LA was included in Uganda’s PrEP guidelines in 2022, its implementation has been slow [6].

Despite CAB-LA demonstrating effectiveness in clinical trials, there is limited research associated with the willingness of adolescent girls and young women in education institutional settings, such as schools and universities, to use long-acting PrEP for HIV prevention, yet this particular population is vulnerable to HIV acquisition, with a prevalence rate of 1.5% compared to 0.9% among men%) [7]. This is made worse by the predominant focus on other groups, such as men who have sex with men, cisgender individuals, and people who use drugs, ignoring this vulnerable population [8, 9]. This study specifically targets female university students because prior research has indicated a heightened risk of STIs within this demographic [10]. Awareness of injectable PrEP among high-risk adolescent girls and young women in Kampala, Uganda, is notably low, with only 3.9% reporting familiarity with the method [11]. Therefore, this low awareness not only limits their access to effective HIV prevention strategies but also perpetuates a cycle of vulnerability to HIV infection. Increasing awareness and education about PrEP is essential to empower this demographic and reduce their risk. However. this study aimed to assess the willingness of female students at a Ugandan public university to use long-acting Cabotegravir (CAB-LA) for HIV prevention.

Methods

Study setting and design

A cross-sectional study collected the data between April and June 2024. In total, we surveyed 346 female undergraduate students. This was determined using Cochran’s formula at an 80% power, 95% confidence level, and 0.05 precision; Inline graphic [12] The study was conducted at Makerere University College of Health Sciences in Kampala, Uganda, one of Africa’s oldest universities. Some students from urban and affluent families have access to better educational resources, while others come from rural and lower-income backgrounds. The students can access free HIV prevention services from the University hospital. We focused exclusively on female undergraduate students from the Faculty of Health Sciences at Makerere University because we believe that these students possess a greater understanding of HIV prevention strategies related to their medical training. They are expected to knowledge of CAB-LA as a PrEP strategy.

Only female undergraduate students aged 18–25 who self-reported to be HIV negative consented to participate in the study. After assessing their eligibility criteria, an online data collection tool developed using the Kobo toolbox was shared via the students’ email addresses or WhatsApp according to their preference.

We excluded those with a dead year and those absent during the study. Consecutive sampling was used to enroll participants from all the schools at Makerere University College of Health Sciences, i.e., School of Biomedical Sciences, School of Dentistry, School of Public Health, School of Health Sciences, and School of Medicine. Participants from all academic years, including years one to five, were considered for the study. The study team developed a data collection tool based on existing literature. The newly developed tool assessed willingness to use CAB-LA with three 5-level Likert scale questions based on existing literature. Scores ranged from 1 (very unwilling) to 5 (very willing), with higher scores indicating greater willingness. Scores were summed and dichotomised at the 50th percentile (score of 9), with scores above 9 indicating willingness to use CAB-LA [13].

Data management and analysis

The data collection tool was designed using Kobo Collect software, and data analysis was done using STATA version 17.0. A modified Poisson regression analysis assessed the association between the willingness to use CAB-LA and independent variables. This method provides accurate relative risks for common events (prevalence > 10%), unlike logistic regression, which can overestimate them [14]. Unadjusted analysis estimated crude prevalence ratios (cPR) and 95% confidence intervals (CI). Independent variables with a P value < 0.2 were considered for adjusted analysis. The final model used a significance level of P value 0.05, reporting adjusted prevalence ratios (aPR) and their 95% CI.

Results

Demographic, sexual and behavioural characteristics of the study participants

Table 1 shows the demographic, sexual and behavioural characteristics of the female students.

Table 1.

Demographic, sexual and behavioural characteristics of female undergraduate students at a Ugandan public university (N = 346)

Demographic characteristic Categories Frequency (N = 346) (%)
Age (completed years) Median (IQR) 23 (22, 25)
Year of Study 1st Year 70 20.2
2nd Year 62 17.9
3rd Year 91 26.3
4th Year 94 27.2
5th Year 29 8.4
Residence status On-Campus Resident 186 53.8
Non-Resident 160 46.2
Religion Christian 312 90.2
Non-Christian 34 9.8
Sponsor Government-sponsored 206 59.7
Private with Scholarship 41 11.9
Private without Scholarship 98 28.4
Marital status Married/Live with partner 31 9.0
Not Married 315 91.0
Sexual and behavioural characteristics Categories Frequency (N = 246) (%)
Ever been pregnant Yes 21 6.1
Ever used a contraceptive method Yes 89 25.7
Contraceptive method previously used* Condoms 31 34.9
Emergency pills 42 47.2
Injectable 1 1.1
Intra-uterine device 5 5.6
Natural methods 5 5.6
Oral pills 5 5.6
Sexual activity (past 3 months$) Yes 197 57.3
Number of sexual partners in the past 3 months@ One partner 146 74.1
> one partner 51 25.9
Primary partner having other sexual partners@ Yes 19 9.7
Knowledge about HIV status of the primary partner@ Yes 164 83.3
HIV status of the partner# Positive 1 0.6
Used injectable recreational drugs (past 6 months) Yes 13 3.8
Ever tested for HIV (past 12 months) Yes 227 65.6
Disclosure of HIV status to partner (s)## Yes 183 81.7
Age difference with the primary partner^ < 10 years 80 41.0
Ever heard about HIV prevention methods Yes 285 82.4
Access to preferred HIV prevention methods at place of residence Yes 222 64.2
Alcohol use in the past 6 months Yes 103 29.8
Perceived HIV risk High risk 35 10.1
Low risk 187 54.1
Not at risk 124 35.8
Ever heard about HIV PrEP% Yes 262 76.2
Ever used HIV PrEP** Yes 9 3.4

*N = 89, $N = 344, @N = 197, #N = 162, ##N = 224, ^N = 195, %N = 344, **N = 262, %=percentage

Willingness to use CAB-LA and associated factors

The median willingness to use CAB-LA score was 10 (IQR: 6 to 15). Of the female university students, 56.7% (95% CI: 51.4 to 61.8) were willing to use CAB-LA.

Table 2 shows the analysis of the factors associated with willingness to use CAB-LA.

Table 2.

Adjusted and unadjusted analysis of demographic factors associated with willingness to use CAB-LA among female students at a Ugandan public university (N = 346)

Variable Categories cPR (95% CI) P value aPR (95% CI) P value
Year of Study 1st Year Ref Ref
2nd Year 1.00 (0.71, 1.41) 1.000 1.04 (0.74, 1.46) 0.825
3rd Year 0.97 (0.71, 1.33) 0.836 0.98 (0.72, 1.34) 0.906
4th Year 1.38 (1.06, 1.81) 0.019 1.34 (1.03, 1.75) 0.032
5th Year 1.45 (1.05, 2.01) 0.026 1.31 (0.95, 1.80) 0.105
Religion Christian Ref
Non-Christian 0.65 (0.42, 1.01) 0.055
Marital status Married Ref
Not married 0.92 (0.68, 1.23) 0.566
Sexual activity - past 3 months Not Sexually active Ref Ref
Sexually active 1.34 (1.10, 1.64) 0.004 1.25 (1.01, 1.53) 0.038
HIV test in the past 12 months Yes 1.49 (1.18, 1.88) 0.001
Knows partner’s HIV status Yes 1.29 (0.91, 1.83) 0.153
Alcohol use in the past 6 months Yes 1.37 (1.15, 1.64) < 0.001 1.24 (1.03, 1.49) 0.023
Self-perceived HIV risk No HIV risk Ref
Low HIV risk 1.24 (0.90, 1.72) 0.196
High HIV risk 1.27 (1.03, 1.58) 0.029
Access to preferred HIV prevention methods at place of residence Yes 0.85 (0.70, 1.02) 0.072
Ever heard about HIV PrEP Yes 1.22 (0.96, 1.56) 0.109

Discussion

This study assessed the willingness of female university students to use CAB-LA and the associated factors. Over half of the participants were willing to use CAB-LA, which is sub-optimal for large-scale implementation. Higher willingness was previously reported in studies among key and minority populations. For example, acceptability varied by demographics, with a higher preference among males, especially men who have sex with men (MSM) in the US, and females outside the US [15], as well as in Africa [16]. The differences in willingness across populations may be due to the higher prevalence and acceptance of PrEP among high-risk groups [17, 18]. Female health profession students may not perceive themselves as high risk, as only 10.1% felt they were at high risk of HIV. This highlights the need for targeted education and awareness campaigns to increase PrEP uptake among broader populations, including university students.

This study showed a higher willingness to use CAB-LA compared to a study in the US, where only 32.4% [19] were willing, as well as in Nigeria, where 50.1% of the youth (14–24 years) were willing [20]. The higher willingness in our study may be due to the participants being female and more likely to seek reproductive health services [21]. This suggests that educational initiatives about HIV prevention are effective and that there may be a supportive environment for implementing CAB-LA programs in Uganda. Future research should assess the willingness of male university students to use CAB-LA.

Fourth-year female students are 1.34 times more likely to use CAB-LA for HIV prevention compared to first-year female students. Their greater education and clinical experience enhance their understanding of HIV prevention and the benefits of long-acting PrEP. However, a study found that healthcare professional students were less willing to prescribe PrEP as they advanced in their programs [22]. Addressing this early can help develop interventions to ensure healthcare providers support PrEP use. Therefore, medical schools and policymakers should consider focusing educational interventions on HIV prevention during the early stages of training.

Sexually active female health professional students were 25% more willing to use CAB-LA compared to their non-sexually active peers. This aligns with findings from a study on oral PrEP predictors [23]. Factors contributing to this include their medical training, access to current HIV prevention information, and the convenience of less frequent dosing with Long-acting PrEP. The higher willingness among sexually active individuals may also relate to their increased HIV risk [24]. Healthcare providers should regularly discuss sexual health with university students to tailor prevention strategies. Further research should explore the broader implications of sexual practices and HIV risk, with longitudinal studies examining evolving attitudes towards Long-acting PrEP and its impact on HIV prevention.

High alcohol consumption is linked to risky sexual behaviour, with drinkers being more likely to engage in transactional sex and have multiple or concurrent partnerships [25]. The cognitive effects of alcohol impair judgment, leading to risky behaviours that increase HIV transmission risk [26]. Social factors, such as peer influence and discussions about sexual health within social circles, also play a role. Peer-led initiatives targeting those who consume alcohol could be beneficial in increasing awareness and willingness to use HIV prevention measures like CAB-LA [27].

The study’s focus on health profession students at one public university limits its generalizability. Future research should use longitudinal designs.

Acknowledgements

The authors acknowledge the study participants for having participated in the study.

Author contributions

BA contributed to the conception, data acquisition, analysis, interpretation, and manuscript drafting. LM and RN were involved in the study design, data analysis, and critical revision of the manuscript. PM and TDN provided supervision and contributed to data analysis, interpretation, and manuscript drafting. CPO and RM contributed to data interpretation and critical revision of the manuscript. All the authors gave final approval for the work to be published. All authors agree to be accountable for all aspects of the work and to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding

BA received an IRB research grant from the Department of Nursing at Makerere University. Additionally, PAM received a MAK-ImS implementation science fellowship, and the project was funded by the European and Developing Countries Clinical Trials Partnership (EDCTP) - Grant Number: CSA2018HS-2518 and the National Institutes of Health’s Fogarty International Center - Award Number D43TW010037. The funders had no role in study design, data collection and analysis, publication decisions, or manuscript preparation. The contents are solely the authors’ responsibility and do not necessarily represent the official views of the supporting institutions.

Data availability

The datasets used or analysed during the current study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

This study protocol and tools were approved by the Makerere University School of Health Sciences Research Ethics Committee (MAKSHSREC-2024-665). The principal of the College of Health Sciences and the Department of Nursing at Makerere University also granted permission to conduct the study. Participants provided electronic consent before participating in the study. Participation was voluntary, without consequences for those who chose not to participate. All methods followed relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Nasioho Faith Makhakho YS. Anna Meyer Weitz: Whatever is in the ARVs, is also in the PrEP challenges associated with oral pre-exposure prophylaxis use among female sex workers in South Africa. frontiers 2022. [DOI] [PMC free article] [PubMed]
  • 2.Heffron R, Muwonge TR, Thomas KK, Nambi F, Nakabugo L, Kibuuka J, et al. PrEP uptake and HIV viral suppression when PrEP is integrated into Ugandan ART clinics for HIV-negative members of HIV-serodifferent couples: a stepped wedge cluster randomized trial. EClinicalMedicine 2022;52:101611 [DOI] [PMC free article] [PubMed]
  • 3.Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Moyo EMG, Musuka G, Dzinamarira T. Long-acting injectable drugs for HIV-1 pre-exposure prophylaxis: considerations for Africa. tropicalmed7080154 PMID 2022. [DOI] [PMC free article] [PubMed]
  • 6.MoH. Consolidated guidelines for the prevention and treatment of HIV and AIDS in Uganda. In. Uganda; 2022.
  • 7.Mayega RW, HIV Sero-behavioral study in six universities in Uganda, final report. EAC/AMREF lake Victoria partnership programme 2010:193.
  • 8.Schoenberg P, Edwards OW, Merrill L, Martinez CA, Stephenson R, Sullivan PS, Jones J. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross‐sectional study. J Int AIDS Soc. 2023;26(3):e26077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Nabunya R, Karis VM, Nakanwagi LJ, Mukisa P, Muwanguzi PA. Barriers and facilitators to oral PrEP uptake among high-risk men after HIV testing at workplaces in Uganda: a qualitative study. BMC Public Health. 2023;23(1):365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Rutherford GW, Anglemyer A, Bagenda D, Muyonga M, Lindan CP, Barker JL, Johnston L, Hladik W. University students and the risk of HIV and other sexually transmitted infections in Uganda: the Crane Survey. Int J Adolesc Med Health. 2014;26(2):209–15. [DOI] [PubMed] [Google Scholar]
  • 11.Lunkuse JF, Kamacooko O, Muturi-Kioi V, Chinyenze K, Kuteesa MO, Price MA, Mayanja Y. Low awareness of oral and injectable PrEP among high-risk adolescent girls and young women in Kampala, Uganda. BMC Infect Dis. 2022;22(1):467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Cochran WG. Sampling techniques. Johan Wiley & Sons Inc; 1977.
  • 13.Ninsiima M, Nyabigambo A, Kagaayi J. Acceptability of integration of cervical cancer screening into routine HIV care, associated factors and perceptions among HIV-infected women: a mixed methods study at Mbarara Regional Referral Hospital, Uganda. BMC Health Serv Res. 2023;23(1):333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Callas PW, Pastides H, Hosmer DW. Empirical comparisons of proportional hazards, poisson, and logistic regression modeling of occupational cohort data. Am J Ind Med. 1998;33(1):33–47. [DOI] [PubMed] [Google Scholar]
  • 15.Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R. Acceptability of long-acting injectable cabotegravir (CAB LA) in HIV-uninfected individuals: HPTN 077. AIDS Behav. 2020;24:2520–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and preferences for Long-Acting Injectable HIV PrEP and other PrEP modalities among sexual minority men in Nigeria, Africa. AIDS Behav. 2022;26(7):2363–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hollcroft MR, Gipson J, Barnes A, Mena L, Dombrowski JC, Ward LM, Khosropour CM. PrEP Acceptance among eligible patients attending the largest PrEP clinic in Jackson, Mississippi. J Int Association Providers AIDS Care (JIAPAC). 2023;22:23259582231167959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Spinner CD, Hanhoff N, Krznaric I, Knecht G, Kuemmerle T, Ruesenberg R, Schewe K. 2016 PREP attitudes in Germany: high awareness and acceptance in MSM at risk of HIV. Infection. 2018;46:405–8. [DOI] [PubMed] [Google Scholar]
  • 19.Zarwell M, Patton A, Gunn LH, Benziger A, Witt B, Robinson PA, et al. PrEP awareness, willingness, and likelihood to use future HIV prevention methods among undergraduate college students in an ending the HIV epidemic jurisdiction. J Am Coll Health 2023:1–10. [DOI] [PubMed]
  • 20.Gbaja-Biamila T, Obiezu-Umeh C, Nwaozuru U, Rosenberg NE, Igbokwe M, Oladele D, Musa AZ, Idigbe I, Conserve D, Day S, et al. Awareness of, willingness to use, and experiences with pre-exposure prophylaxis among youth in Nigeria. BMC Health Serv Res. 2024;24(1):1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Otwombe K, Dietrich J, Laher F, Hornschuh S, Nkala B, Chimoyi L, Kaida A, Gray GE, Miller CL. Health-seeking behaviours by gender among adolescents in Soweto, South Africa. Global Health Action. 2015;8(1):25670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Przybyla S, Fillo J, Kamper-DeMarco K, Bleasdale J, Parks K, Klasko-Foster L, Morse D. HIV pre-exposure prophylaxis (PrEP) knowledge, familiarity, and attitudes among United States healthcare professional students: a cross-sectional study. Prev Med Rep. 2021;22:101334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Muhumuza R, Ssemata AS, Kakande A, Ahmed N, Atujuna M, Nomvuyo M, Bekker L-G, Dietrich JJ, Tshabalala G, Hornschuh S. Exploring perceived barriers and facilitators of PrEP uptake among young people in Uganda, Zimbabwe, and South Africa. Arch Sex Behav. 2021;50(4):1729–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sevelius JM, Poteat T, Luhur WE, Reisner SL, Meyer IH. HIV testing and PrEP use in a national probability sample of sexually active transgender people in the United States. JAIDS J Acquir Immune Defic Syndr. 2020;84(5):437–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bello B, Moultrie H, Somji A, Chersich MF, Watts C, Delany-Moretlwe S. Alcohol use and sexual risk behaviour among men and women in inner-city Johannesburg, South Africa. BMC Public Health. 2017;17(Suppl 3):548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rehm J, Shield KD, Joharchi N, Shuper PA. Alcohol consumption and the intention to engage in unprotected sex: systematic review and meta-analysis of experimental studies. Addiction. 2012;107(1):51–9. [DOI] [PubMed] [Google Scholar]
  • 27.He J, Wang Y, Du Z, Liao J, He N, Hao Y. Peer education for HIV prevention among high-risk groups: a systematic review and meta-analysis. BMC Infect Dis. 2020;20:1–20. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used or analysed during the current study are available from the corresponding author upon reasonable request.


Articles from AIDS Research and Therapy are provided here courtesy of BMC

RESOURCES